FLAURA-2: Early plasma EGFR mutation clearance is prognostic but not predictive of benefit from osimertinib plus chemotherapy

Lung, Respiratory and Thoracic Cancer

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Lancet Oncol

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L

doi: 10.1016/S1470-2045(26)00282-2

Lung, Respiratory and Thoracic Cancer

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

Lancet

Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W, SACHI Study Group

doi: 10.1016/S0140-6736(25)01811-2

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

CHRYSALIS-2: First-line amivantamab plus lazertinib demonstrates durable OS in atypical EGFR-mutated advanced NSCLC

WCLC 2026

Lung, Respiratory and Thoracic Cancer

ADAURA: Adjuvant osimertinib provides OS benefit at eight years in patients with resected EGFR-mutated NSCLC

Lung, Respiratory and Thoracic Cancer

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Lung Cancer

Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, Çİl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC

doi: 10.1016/j.lungcan.2026.109302

CHICAGO 2026

Breast Cancer

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

Lung Cancer

Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK

doi: 10.1016/j.lungcan.2025.108788

ELCC 2026

Lung, Respiratory and Thoracic Cancer

PALOMA-2: Durable clinical outcomes and manageable safety with SC amivantamab plus lazertinib in patients with EGFR-mutated NSCLC

Lung, Respiratory and Thoracic Cancer

Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2

Lung Cancer

Planchard D, Jänne PA, Yang JC, Kobayashi K, Valdiviezo N, Fan Y, Kim TM, Gálvez ML, Nishino K, Biswas B, Feng PH, Sriuranpong V, Koubkova L, Pinto GDJ, Escriu C, Tran TV, Takahashi T, Nerón Y, Han JY, Figueroa A, Donachie V, Khullar A, Evans A, Albayaty M, Lee CK

doi: 10.1016/j.lungcan.2026.109588

Related content

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

CHRYSALIS-2: First-line amivantamab plus lazertinib demonstrates durable OS in atypical EGFR-mutated advanced NSCLC

ADAURA: Adjuvant osimertinib provides OS benefit at eight years in patients with resected EGFR-mutated NSCLC

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

PALOMA-2: Durable clinical outcomes and manageable safety with SC amivantamab plus lazertinib in patients with EGFR-mutated NSCLC

Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2